Dementia Matters

In a special episode of Dementia Matters, Drs. Cynthia Carlsson and Sterling Johnson join the podcast to discuss what they know from lecanemab’s clinical trials following the U.S. Food and Drug Administration’s (FDA) accelerated approval, granted on January 6, 2023. Guests: Cynthia Carlsson, MD, MS, director, Wisconsin Alzheimer’s Institute, and Sterling Johnson, PhD, leader, Wisconsin Registry for Alzheimer’s Prevention (WRAP), associate director, Wisconsin Alzheimer’s Disease Research Center and Wisconsin Alzheimer’s Institute Show Notes This episode was uploaded as an exclusive video episode on the Wisconsin ADRC YouTube page on February 13, 2023. Watch the video interview with Drs. Carlsson and Johnson here. In a previous episode of Dementia Matters, Dr. Chin gave a brief overview of lecanemab’s clinical trials. Listen to it on Spotify, Apple Podcasts, our website, or wherever you listen. Read more about the AHEAD study and A4 study at their respective websites. Connect with us Find transcripts and more a

Former Governor of Wisconsin, Martin Schreiber, returns to Dementia Matters to discuss different methods for communicating with a loved one with Alzheimer’s disease, including therapeutic fibbing. Governor Schreiber has been a widely outspoken advocate for Alzheimer’s disease while caring for his late wife Elaine, who passed away from the disease in April of 2022. In this episode, he also talks about his book, My Two Elaines, where he opens up about his experience as a caregiver. Guest: Martin Schreiber, Former Governor of Wisconsin (1977-1979), Former Lt. Governor of Wisconsin (1971-1977) Show Notes Learn more about Martin Schreiber and his book, My Two Elaines, at his website, or follow him on Facebook. Listen to Governor Schreiber’s previous appearance on our website or wherever you get your podcasts.  Connect with us Find transcripts and more at our website. Email Dementia Matters Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

In October 2022, the Alzheimer's Association named Dr. Joanne Pike, the current president of the Association, as the next CEO, succeeding Harry Johns who has served as CEO since 2005. In this episode, Pike and Johns join the podcast to share their insights on how the Alzheimer's Association has grown over the past few decades and the future plans of the association, as well as the next steps in Alzheimer's treatment from both community and medication perspectives. Guests: Joanne Pike, DrPH, president and CEO, Alzheimer’s Association, Alzheimer’s Impact Movement, and Harry Johns, former CEO, Alzheimer's Association, former CEO and president, Alzheimer's Impact Movement (AIM), trustee and former chair, World Dementia Council Show Notes Learn more about CMS's updated coverage on monoclonal antibody treatment and the Alzheimer's Association’s response at their website. Learn more about Part the Cloud at their website. Learn more about the Alzheimer's Association at their website. Learn more about Dr. Pike in her

Host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials. On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Show Notes In the coming weeks, host Nathaniel Chin will be joined by Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to further discuss lecanemab and the clinical trials’ results. A link to that episode will be added here following its release. Read the FDA’s news release regarding lecanemab’s accelerated approval on their website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Host Nathaniel Chin, MD, starts the new year by discussing modifiable risk factors for Alzheimer’s disease, commenting on building healthy lifestyle habits for the new year, and reflecting as Dementia Matters celebrates five years of production. Show Notes “Dementia prevention, intervention, and care: 2020 report of the Lancet Commission” is mentioned at the 4:16 mark. Read the full report on The Lancet’s website. Our past episode, “Alcohol and the Brain: One Drink a Day Associated with Brain Shrinkage,” is mentioned at the 5:05 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen.  Our past episode, “Study Finds Air Pollution a Risk Factor For Alzheimer’s Disease,” is mentioned at the 5:07 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen. Our past episode, “AARP Study Show Stigma Surrounding Dementia Among Healthcare Professionals And General Public,” is mentioned at the 5:28 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen. As m

It’s generally known that mitochondria are the powerhouse of cells, but did you know they can play a significant role in aging processes? Through the field of bioenergetics, scientists are looking to study how changes in mitochondria affect us as we age and their connection to Alzheimer’s disease. Dr. Russell Swerdlow joins the podcast to discuss the field of bioenergetics and how mitochondria can impact Alzheimer’s disease and other aspects of aging. Guest: Russell Swerdlow, MD, director, Kansas Alzheimer’s Disease Research Center, director, Heartland Center for Mitochondrial Medicine, professor of neurology, University of Kansas Show Notes Learn more about Dr. Russell Swerdlow at his bio on the University of Kansas Medical Center’s website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

The field of biomarkers is advancing quickly, allowing preclinical Alzheimer’s disease to be identified earlier and earlier in a person’s life. As individuals learn they are at risk for Alzheimer’s years or even decades before experiencing cognitive decline, what does this mean for them and for society as a whole? Drs. Emily Largent and Claire Erickson join the podcast to discuss ten key areas, such as healthcare, insurance, and direct-to-consumer testing, that should be addressed to support those at risk for cognitive decline and broader U.S. society as biomarker testing and disclosures become more prominent. Guests: Emily Largent, PhD, RN, Emanuel and Robert Hart Assistant Professor, University of Pennsylvania Perelman School of Medicine, and Claire Erickson, PhD, MPA, postdoctoral fellow, University of Pennsylvania Perelman School of Medicine Show Notes Read Drs. Emily Largent and Claire Erickson’s paper, “Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society,” on P

Though brain and cognitive changes are typically diagnosed as one form of dementia, recent studies have shown that mixed dementia is more common than previously thought. Mixed dementia, also known as Multiple-etiology dementia, is a condition where brain changes are caused by more than one neurological disease, such as Alzheimer’s disease, Lewy body dementia (LBD), or frontotemporal dementia. Dr. Roderick Corriveau joins the podcast to discuss what is known about mixed dementia and how the field of studying neurological diseases is advancing to diagnose and treat this condition. Guest: Roderick Corriveau, PhD, program director, National Institute of Neurological Disorders and Stroke (NINDS), NIH Lead, Alzheimer’s Disease-Related Dementias (ADRD) Summits Show Notes Read more about the National Institutes of Neurological Disorders and Stroke (NINDS) campaign, “Mind Your Risks,” at the Mind Your Risks website. Learn more about mixed dementia on the Alzheimer’s Association website. Learn more about Dr. Corriveau

Though several validated biomarkers are studied and used in Alzheimer’s disease research, most research participants don’t have the opportunity to learn their biomarker results afterward, even if they have cognitive impairment. Drs. Jason Karlawish and Josh Grill join the podcast to discuss the debate over sharing biomarker results with research participants, how these powerful disclosures can be made ethically, and why it's as important for the field to study biomarker disclosures as it is to study the biomarkers themselves. Guests: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, associate professor, University of California, Irvine, and Jason Karlawish, PhD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania Show Notes Read Dr. Jason Karlawish and Dr. Josh Grill’s viewpoint piece, “Disclosing Alzheimer Disease Biomarker Results to Research Participants,” from JAMA Neurology’s June 2022 is

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 6 Concluding our special series on the 2022 Spring ADRC Meeting, Dr. Cerise Elliott joins the podcast to discuss the NIA’s work within the field of Alzheimer’s disease research, how the NIA promotes open science to advance research across the ADRC program, and other key takeaways from the spring meeting. Guest: Cerise Elliott, PhD, program director for clinical interventions and diagnostics, division of neuroscience, National Institute on Aging Show Notes Watch Dr. Cerise Elliott’s session from the Spring ADRC Meeting, “Q&A with Program,” on NACC’s YouTube channel. Listen to our previous episode with Dr. Elliott, "National Priorities for Dementia and Health Disparities Research," on our website. Learn more about Dr. Elliott at her bio on the National Institute on Aging website. Learn more about the National Alzheimer’s Coordinating Center at their website. Connect with us Find transcripts and more at our

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 5 Whether it be due to new research findings, innovative approaches and ideas, or technological advancements, Alzheimer’s disease research is constantly evolving. Now, dementia research is headed into the digital frontier. Dr. Rhoda Au joins the podcast to discuss digital biomarkers, gamifying cognitive testing, and how the field of Alzheimer’s disease research is entering its digital age. Guest: Rhoda Au, PhD, digital technology leader, Boston University Alzheimer’s Disease Research Center, co-principal investigator, director of neuropsychology, Framingham Heart Study, professor, Boston University School of Medicine Show Notes Watch Dr. Rhoda Au’s presentation from NACC’s Spring ADRC Meeting on NACC’s YouTube channel. Learn more about Dr. Au at her bio on the Boston University Chobanian & Avedisian School of Medicine website. Learn more about the National Alzheimer’s Coordinating Center at their website.

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 4 Brain imaging is a key tool in Alzheimer’s disease research and diagnoses, allowing scientists to see changes in the brain years, even decades, before an individual experiences symptoms of dementia. The data these images provide researchers with is incredibly useful, leading the National Alzheimer’s Coordinating Center to take up numerous efforts to standardize, unify and share this type of data across the Alzheimer’s Disease Research Centers. Dr. Beth Mormino joins the podcast to discuss the NIA’s SCAN initiative, the new “legacy” data set, and the importance of standardizing MRI and PET scan procedures to predict brain trajectories better. Guest: Beth Mormino, PhD, assistant professor, Stanford University Show Notes Learn more about Dr. Mormino’s presentation on the SCAN Legacy project by reading her presentation slides on NACC’s website. Listen to Dr. Mormino’s last episode on Dementia Matters, “The Scie

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 3 With big data comes big responsibility. Dr. Sean Mooney joins the podcast to discuss his work with NACC, the precautions NACC takes to keep participant data secure, and how this data can be used to better predict Alzheimer’s disease risk to allow for earlier interventions. Guest: Sean Mooney, PhD, associate director of technology, National Alzheimer’s Coordinating Center, Chief Research Information Officer, UW Medicine, professor, University of Washington Show Notes Watch Dr. Mooney’s talk from NACC’s Spring 2022 Alzheimer’s Disease Research Center Meeting on NACC's YouTube page. Learn more about the National Alzheimer’s Coordinating Center at their website.  Register for NACC’s Fall 2022 ADRC Meeting on their website. Registration is free and open to the public. The fall meeting, which will focus on diversity, equity, and inclusion in Alzheimer’s research, will take place Thursday, October 20th to Friday,

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 2 Dr. Sarah Biber, the program director for NACC, joins the podcast to discuss building a one-stop shop for Alzheimer’s Disease Research Center (ADRC) data and what it means for the future of collaborative Alzheimer’s disease research. Guest: Sarah Biber, PhD, program director, National Alzheimer’s Coordinating Center Show Notes Learn more about Dr. Biber’s talk at NACC’s Spring 2022 Alzheimer’s Disease Research Center Meeting by reading her presentation slides on NACC’s website. Learn more about the National Alzheimer’s Coordinating Center at their website. Register for NACC’s Fall 2022 ADRC Meeting on their website. Registration is free and open to the public. The fall meeting, which will focus on diversity, equity, and inclusion in Alzheimer’s research, will take place Thursday, October 20th to Friday, October 21st both virtually and in-person in Chicago, IL. Connect with us Find transcripts and more at ou

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 1: Kicking off our six-episode series on the National Alzheimer’s Coordinating Center and their Spring 2022 ADRC meeting, Dr. Walter Kukull joins the podcast. He explains what NACC is, what they do with the data they collect from the 42+ Alzheimer’s Disease Research Centers, the center’s biannual ADRC meetings and what he’s most excited about for the next five years of Alzheimer’s disease research. Guest: Walter Kukull, PhD, director, National Alzheimer’s Coordinating Center, professor, University of Washington department of epidemiology Show Notes Learn more about the National Alzheimer’s Coordinating Center at their website.  View slides and video recordings of NACC’s Spring 2022 ADRC Meeting on the NACC website. Register for NACC’s Fall 2022 ADRC Meeting on their website. Registration is free and open to the public. The fall meeting, which will focus on diversity, equity, and inclusion in Alzheimer’s resea

Researchers typically recognize the APOE e4 gene as a significant genetic risk factor for cognitive decline and dementia. However, a new study has found that the allele is not linked to neurodegeneration for all races and ethnic groups, specifically for American Indian populations. Dr. Astrid Suchy-Dicey joins the podcast to discuss her study, the importance of representation in Alzheimer’s disease research, hypotheses for why this allele isn’t a risk factor for all populations and what it means for research going forward. Guest: Astrid Suchy-Dicey, PhD, epidemiologist, assistant research professor, Washington State University, Institute for Research and Education to Advance Community Health (IREACH) Show Notes Read the research highlights of Dr. Suchy-Dicey’s study on the National Institute of Aging website. Read Dr. Suchy-Dicey’s study, “APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study,” through the journal Alzheimer’s & Demen

Research participants are recruited through a variety of practices. One of the most popular tools are registries, but how can registries affect diversity and representation within research? Josh Grill joins the podcast to discuss his work studying research registries, their effects on representation for disadvantaged communities, and how research recruitment and outreach can be improved going forward. Guest: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, associate professor, University of California, Irvine Show Notes Learn more about Dr. Grill at his bio on the University of California - Irvine website. Read Dr. Grill’s study, “Diversifying recruitment registries: Considering neighborhood health metrics,” through the National Library of Medicine website. Learn more about University of California - Irvine's Institute for Memory Impairments and Neurological Disorders (UCI-MIND) on their website. Listen to our episode with Dr. Amy Kind about the link between neighborhood

AAIC Special Series Part 8: Closing out our special series spotlighting the 2022 Alzheimer’s Association International Conference, Dr. Percy Griffin joins the podcast to discuss highlights from this year’s event. Guest: Percy Griffin, PhD, director, scientific engagement, Alzheimer’s Association Show Notes Find more highlights from the conference, including on-demand content that is available to watch through September 1, 2022 at 11:59p.m. PT , at the AAIC website. Learn more about Dr. Percy Griffin at his bio on the Alzheimer’s Association website. Listen to our AAIC special series episode with Dr. Carl Hill, mentioned by Dr. Chin at 3:41, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen. Listen to our AAIC special series episode with Dr. Heather Snyder, mentioned by Dr. Chin at 18:22, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen Find the news highlights on diet, racism, preeclampsia, COVID-19, and more mentioned by Dr. Chin at the AAIC website. Connect wit

AAIC Special Series Part 7: Recent studies have shown that 1 in 5 U.S. adults who were diagnosed with COVID-19 now deal with Long COVID, a condition where individuals report fatigue, cognitive issues, difficulty breathing, and other symptoms lasting at least three months after infection. With these reported effects on cognition and brain health, what else do we know about COVID’s impact on the brain? Dr. Heather Snyder joins us to talk about what we know about COVID-19’s effects on the brain and her upcoming scientific session at AAIC 2022. Guest: Heather Snyder, PhD, vice president, medical & scientific relations, Alzheimer’s Association Show Notes AAIC is the world’s largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Read more about Dr. Snyder at her bio on the Alzheimer’s Association website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc

AAIC Special Series Part 6: Dr. Krista Lanctôt joins the podcast to discuss apathy, how it develops in people with Alzheimer’s disease, and her upcoming AAIC 2022 plenary talk. Guest: Krista Lanctôt, PhD, senior scientist, Sunnybrook Health Sciences Centre, full professor, University of Toronto Show Notes AAIC is the world’s largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Lanctot at her bio on the University of Toronto website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.